Fulcrum Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held on June 24, 2026. The filing covers the election of directors, executive compensation advisory votes, and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
The following matters were voted on by stockholders:
- Director Elections: Stockholders elected Sonja Banks, Alan Ezekowitz, and Colin Hill as Class I directors for three-year terms ending in 2029.
- Executive Compensation: Stockholders approved, on a non-binding advisory basis, the compensation of named executive officers.
- Auditor Ratification: Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Director Support: Alan Ezekowitz and Colin Hill received over 52 million votes "For," while Sonja Banks received approximately 43 million votes "For" with over 10 million votes withheld.
- Compensation Vote: The advisory vote on executive compensation received approximately 50.7 million votes "For" and 3 million votes "Against."
- Auditor Approval: The ratification of Ernst & Young LLP was overwhelmingly supported with nearly 58.8 million votes "For" and only 36,178 votes "Against."
- Broker Non-Votes: There were 5,062,117 broker non-votes recorded for the director elections and the executive compensation vote.